Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK1 Recombinant Protein / Active Kinase Complex High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CDK1 Products |
| Mutant Kinase | CDK1 Mutant Recombinant Proteins (Gateway & activation-loop variants) Sequence Verified, High Purity (>95%). Essential for resistance profiling. |
View CDK1 Products |
| Gene Delivery | CDK1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CDK1 Products |
| Benchmark Ab | Anti-CDK1 Biosimilar Antibody Recombinant positive control. |
View CDK1 Products |
| Validator | CDK1 siRNA Set For knockdown verification. |
View CDK1 Products |
| Related Target A | CDK2 Crucial for pan-CDK selectivity counter-screening and redundancy analysis. |
View CDK2 Products |
| Related Target B | CDK4 Key cell cycle regulator for broad-spectrum kinase profiling. |
View CDK4 Products |
| Related Target C | CCNB1 (Cyclin B1) Essential CDK1 binding partner; required for functional holoenzyme assembly. |
View CCNB1 Products |
| Related Target D | WEE1 Kinase Synthetic lethal combination partner; key for G2/M checkpoint targeting. |
View WEE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-CDK Cross-Reactivity | Comprehensive CDK homolog panel proteins strictly verified by mass spec and purity assays. |
| Kinase Activity Validation | Co-expressed CDK1/Cyclin complexes available to ensure native-like biological activity. |
| Lack of Controls | Clinical Benchmark Antibodies and small molecule standards included. |
| False Positives | Validated siRNA included for specificity checks in cellular assays. |
| Resistance Mutation Profiling | CDK1 mutant recombinant proteins (gatekeeper and activation-loop variants) available for selectivity and resistance assays. |
Live CDK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK1 therapeutics is intensifying, with major players shifting focus from early-generation pan-CDK inhibitors (which faced severe dose-limiting toxicities like myelosuppression and GI toxicity) to next-generation modalities emphasizing selectivity and synthetic lethality. While first-generation CDK4/6-targeted therapies have matured, the next wave of R&D is targeting CDK1-centric vulnerabilities in MYC-driven and TP53-mutant malignancies, alongside combination regimens with WEE1 and CHK1 inhibitors. Precise structural differentiation through allosteric sites and covalent targeting are emerging strategies to spare essential hematopoietic functions while maximizing anti-tumor efficacy in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Pfizer, Novartis, Eli Lilly | Advanced Solid Tumors, Breast Cancer | Selectivity Assay (Need High-Purity Homolog Proteins) |
| Covalent / Irreversible Inhibitor | Emerging biotech, structure-based design programs | Refractory solid tumors | Binding Kinetics & Cysteine Reactivity (Need pure CDK1 with intact kinase fold) |
| PROTAC / Degrader | Kymera, Arvinas | Treatment-Resistant Carcinomas | Degradation Assays (Need specific cellular knockdown tools) |
| Combination Therapy | AstraZeneca, Daiichi Sankyo | Ovarian Cancer, CRC | Synergy Validation (Need reliable multi-target reference proteins) |